COMPANY

Immunitas Therapeutics

HQ: Waltham, MA source · immunitastx.com ↗

Keywords: oncology solid tumors immunology autoimmune disease Non Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Triple Negative Breast Cancer Cutaneous Squamous Cell Carcinoma Hormone Receptor Positive Breast Carcinoma Small Bowel Cancer Esophageal Cancer Colorectal Cancer Diffuse Large B Cell Lymphoma Hodgkin Lymphoma Burkitt Lymphoma Follicular Lymphoma IMT-009

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Nov 28, 2022 Trial start Phase 1/Phase 2: Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05565417	Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Phase 1/Phase 2	Active, not recruiting	Nov 28, 2022	2026-01 (estimated)

Connect

See your connections at Immunitas Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-04